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of standard cell separation techniques to enrich or deplete
the stem cell product of speciﬁc cell types before trans-
plantation into NSG hosts. Of particular interest are myeloid
lineage cells, such as CD34þ progenitor cells and CD14þ
monocytes, which have been previously described as
harboring latent HCMV [11]. Deﬁning the cell populations
that harbor latent HCMV may lead to novel strategies to
prevent transmission during PBSCT.
Why only 15%-20% of seropositive donors successfully
transmit HCMV to seronegative recipients is not clear. The
previous lackof an experimentalmodel limited the analysis of
transmission to retrospective clinical studies. The NSGmouse
model now permits the experimental evaluation of factors
inherent to the allograft that have been found to correlate
with transmission in such studies [5]. In addition, this model
provides a tool for testing novel hypotheses, such as whether
the risk of transmission is related to the quantitative viral load
in the allograft. Thus, theNSGmousemodel provides a unique
opportunity to gain further insight into the fundamental
mechanisms of HCMV transmission and latency after PBSCT.
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Survivala b s t r a c t
We report the long-term results of a prospective randomized study on the use of ursodeoxycholic acid
(UDCA) for prevention of hepatic complications after allogeneic stem cell transplantation. Two hundred
forty-two patients, 232 with malignant disease, were randomized to receive (n ¼ 123) or not to receive
(n ¼ 119) UDCA from the beginning of the conditioning until 90 days post-transplantation. The results were
reported after 1-year follow-up. UDCA administration reduced signiﬁcantly the proportion of patients
developing high serum bilirubin levels as well as the incidence of severe acute graft-versus-host disease
(GVHD), liver GVHD, and intestinal GVHD. In the UDCA prophylaxis group, nonrelapse mortality (NRM) was
lower and overall survival better than in the control group. After a 10-year follow-up, the difference in the
survival and NRM in favor of the UDCA-treated group, seen at 1 year, was maintained (survival 48% versus
38%, P ¼ .037; NRM 28% versus 41%, P ¼ .01). A landmark analysis in patients surviving at 1 year post-
transplantation showed no signiﬁcant differences between the study groups in the long-term follow-up
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http://dx.doi.org/10.1016/j.bbmt.20in chronic GVHD, relapse rate, NRM, disease-free survival, or overall survival. These long-term results
continue to support the useful role of UDCA in the prevention of transplant-related complications in
allogeneic transplantation.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION irradiation, yes or no), and center. Low-risk patients were those with acute
Liver problems are common after allogeneic stem cell
transplantation. Veno-occlusive disease of the liver (or si-
nusoidal obstruction syndrome) and liver graft-versus-host
disease (GVHD) are the most serious complications. In 1996
to 1998, the Nordic Bone Marrow Transplantation Group
carried out a prospective randomized study to evaluate the
possible role of ursodeoxycholic acid (UDCA) in the preven-
tion of liver complications [1]. UDCA is a hydrophilic bile acid
constituting less than 5% of bile acids in the normal bile [2].
The proportion can be increased to 40% to 50% by oral
administration [2]. The concentration of hydrophobic bile
acids is thereby reduced [3-5]. Hydrophobic bile acids are
toxic to liver parenchymal cells in direct contact that takes
place in disorders damaging bile ducts, whereas hydrophilic
bile acids are nontoxic. UDCA has also been shown to affect
the release and expression of inﬂammatory cytokines [6,7]
and the hepatocyte anion transporters of conjugated bili-
rubin [8], to activate the glucocorticoid receptor [9], to have
immunomodulatory effects [2,7], and to stabilize hepatocyte
membranes [10]. These effects may have a role in the pre-
vention of liver problems.
In the present study, analyzed and reported after a 1-year
follow-up [1], UDCA administration reduced signiﬁcantly the
proportion of patients developing high serum bilirubin levels
as well as the incidence of severe acute GVHD, liver GVHD,
and intestinal GVHD. The incidence of serious liver problems
was lower than among the control patients. In the study
group given UDCA prophylaxis, nonrelapse mortality (NRM)
was signiﬁcantly lower and overall survival signiﬁcantly
better than in the control group. The survival beneﬁt was
seen especially among the low-risk patients. No adverse ef-
fects of UDCA were observed.
The clinical beneﬁts obtained with UDCA prophylaxis in
the ﬁrst year post-transplantation were marked, and a long-
term follow-up was indicated to study whether the reduc-
tion in NRM and improvement in survival was maintained in
the following years. The reduction in acute GVHD indicated a
possible immunological effect that might have an inﬂuence
on chronic GVHD, relapse rate, or the incidence of secondary
neoplasms. Therefore, a long-term follow-upwas carried out.METHODS
The present study was a prospective, randomized, open-label multi-
center study. All patients undergoing allogeneic hematopoietic stem cell
transplantation during the period from January 1996 to November 1998 at
the 3 participating centers, a total of 244 patients, were randomized (1:1) to
receive or not to receive UDCA. The randomization was carried out in blocks
of 4 in sealed opaque envelops to ensure balance between the groups. One
patient in each arm did not undergo the transplantation, 1 because of death
and 1 due to cancellation of the procedure. The randomizationwas stratiﬁed
according to the disease category (low or high risk), type of donor (HLA-
identical sibling, other related, or unrelated), conditioning (total bodyedgments on page 138.
equests: Tapani Ruutu, Division of He-
e, Helsinki University Central Hospital,
, FIN-00029 HUS, Helsinki, Finland.
us.ﬁ (T. Ruutu).
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13.10.014leukemia in ﬁrst remission, chronic myeloid leukemia in ﬁrst chronic phase,
aplastic anemia, or hereditary disorder. All others were high-risk patients.
The primary endpoint was the maximum total bilirubin concentration
during the ﬁrst 90 days [1]. The patients gave their informed consent, and
the study was approved by the ethics committee of each participating
center. Patients were informed and recruited by the treating physician or
responsible investigator.
The long-term outcome of 242 patients was studied. In addition, sepa-
rate analyses were performed among the 156 patients who survived at 1
year post-transplantation to study the possible effect of UDCA prophylaxis
on the later outcome.
One hundred twenty-three patients were randomized to receive and 119
not to receive UDCA (Leiras, Helsinki, Finland). The dose was 12 mg/kg/day,
given from the day preceding the conditioning until day 90 after the
transplantation. Two hundred thirty-two patients had a malignant disease.
Seventy-two patients had acute myeloid leukemia, 68 chronic myeloid
leukemia, 50 acute lymphatic leukemia, 23 myelodysplastic syndrome, 5
multiple myeloma, 4 chronic lymphatic leukemia, 4 non-Hodgkin lym-
phoma, 3 myeloﬁbrosis, and 13 other disease. Seventy-ﬁve patients in the
UDCA group and 65 patients in the control group were low-risk patients.
Detailed demographics of the patients were described in the original article
[1]. All patients with a malignant disease received standard myeloablative
conditioning, in 219 cases based on total body irradiation. Six patients in the
UDCA-treated group and 11 in the control group received busulfan. The
donor was an HLA-identical sibling in 55%, unrelated in 45%, and other
family member in 1% of the transplantations. The graft was bone marrow in
79% and peripheral blood stem cells in 21% of the cases. GVHD prophylaxis
consisted of cyclosporine and a short course of methotrexate with or
without corticosteroid in all but 4 patients.
Data were collected retrospectively after the initial 1-year prospective
phase. Themedian follow-up of living patients was 155months (range, 37 to
184 months). One patient in each study group was lost for follow-up, at 56
and 37 months. The participating centers record the status of their patients
annually for 10 years after the transplantation and thereafter every second
year. We report here the follow-up for 10 years. The parameters studied
were the incidence and grade of chronic GVHD [11], signiﬁcant liver prob-
lems, NRM, relapse rate, disease-free survival, overall survival, secondary
malignancies, and causes of death.
The cumulative incidence of chronic GVHD, relapse, NRM, and survival
were analyzed by Kaplan-Meier curves and compared by the log-rank test.
Relapse and NRMwere assessed using a competing risk analysis [12,13]. The
proportions between the groups were compared by the chi-square test or
Fisher’s exact test. Because of multiple testing of clinical endpoints, P values
adjusted according to Benjamini-Hochberg false discovery rate [14] are also
given.RESULTS
The survival difference seen at 1 year in favor of the UDCA-
treated group (71% versus 55%) remained similar in the long-
term follow-up. At 10 years, 48% of patients given UDCA and
38% of control patients were alive (P ¼ .037, adjusted for
multiple testing .047) (Figure 1A). The survival differencewas
marked among the low-risk patients, 63% versus 46%, P¼ .019
(adjusted .038) (Figure 1B), whereas there was no difference
among the high-risk patients, 25% versus 29% (Figure 1C). The
difference in NRM observed at 1 year (UDCA prophylaxis 19%
versus control group 34%) was maintained through the
follow-up. In the total patient material, the cumulative in-
cidences ofNRMat 10 yearswere28% versus 41%, respectively
(P ¼ .01, adjusted .038) (Figure 2).
There was no signiﬁcant difference in the incidence or
severity of chronic GVHD; the cumulative incidence was 58%
in the UDCA group and 68% in the control group (P ¼ .47). In
the long-term follow-up, past 1 year after the trans-
plantation, there were no signiﬁcant differences in new liver
problems between the study groups.
Figure 1. Overall survival in the whole patient group (A), in low-risk patients (B), and in high-risk patients (C) according to the administration of UDCA prophylaxis.
Figure 2. NRM according to the administration of UDCA prophylaxis.
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the arms. The cumulative incidence at 10 years was 36%
versus 37% in the groups given and not given UDCA, in the
low-risk group 27% versus 26%, and in the high-risk group
54% versus 50%, respectively. Therewere 4 secondary cancers
in the group given UDCA and 7 in the control group.
The causes of death after 1 year post-transplantation in
the study groups given and not given UDCA were the
following (number of patients): GVHD 4 versus 4, infection 5
versus 6, relapse 17 versus 10, EBV lymphoproliferation
0 versus 1, secondary malignancy 2 versus 0, and other
(respiratory insufﬁciency, pancreatitis, myocardial infarction,
heart failure, suicide) 4 versus 3.
A landmark analysis, carried out in patients surviving at 1
year post-transplantation, did not reveal any signiﬁcant dif-
ferences between the study groups in relapse rate, NRM,
disease-free survival, or overall survival (details not shown).
DISCUSSION
The improved survival of patients given UDCA prophy-
laxis was due to reduced NRM in the early phase, during the
ﬁrst year, and this effect was maintained throughout the 10-
year follow-up period. The reduction of NRM was mainly
based on reduced incidence of liver toxicity and severe acute
GVHD. In a landmark analysis among patients alive at 1 year,
no signiﬁcant differences in the outcome parameters were
observed between the study groups during the long-term
follow-up. UDCA did not cause any short- or long-term
adverse effects.
Limitations of this report are the retrospective nature of
the study as well as the open-label design of the trial.However, the main endpoints, survival and NRM, are robust
and not likely to have been signiﬁcantly affected by the po-
tential weaknesses of the study structure. Multiple testing of
clinical outcomes has been taken into account in the statis-
tical analysis.
The reported clinical effects of UDCA prophylaxis have
been somewhat inconsistent [15-20]. This may be due to
differences in patient population, conditioning, other com-
ponents of treatment, outcome in the comparator arm, and
the size of the studies. In a systematic review and pooled
analysis of controlled clinical trials of the prophylactic use of
UDCA, Tay et al. [20] found a signiﬁcantly reduced proportion
of patients with hepatic veno-occlusive disease as well as
signiﬁcantly reduced transplant-related mortality. There was
T. Ruutu et al. / Biol Blood Marrow Transplant 20 (2014) 128e138138a nonsigniﬁcant trend toward a lower incidence of acute
GVHD. No signiﬁcant difference was seen in survival. In the
present study, we did not observe any effect of UDCA on the
incidence of veno-occlusive disease, likely due to the overall
low incidence in our patient material. An important reason
may also be the conditioning, which was mainly based on
total body irradiation; only a few patients received busulfan.
In the present study, the reduced incidence of NRM by UDCA
prophylaxis also resulted in improved survival. In the pooled
analysis by Tay et al. [20], there was a trend toward better
survival, but no signiﬁcant effect was seen. The difference is
possibly due to patient numbers; the present study is the
largest one published on the use of UDCA prophylaxis in
allogeneic transplantation.
The beneﬁts from UDCA were seen in the low-risk group,
whereas there was only a small nonsigniﬁcant trend in the
high-risk group [1]. The reasons for this may not be fully
obvious, but a possible explanation could be that the increased
risks of the disease itself and the toxicity burden from the
preceding treatmentsmaydilute thebeneﬁcial effectsofUDCA.
There appears to be no reason to limit UDCA prophylaxis to
low-(disease) risk patients. The beneﬁts in an individual pa-
tient are not easily predictable, the disease-based stratiﬁcation
may not have been optimal for the prediction of the effects of
UDCA, no negative effects were seen on any outcome param-
eter, practically no side effects occurred, the oral administra-
tion is easy, and the drug is inexpensive.
In the present trial, the administration of UDCA was
initiated on the day preceding the ﬁrst dose of conditioning.
It is known, however, that in healthy adults it takes several
days of UDCA therapy to achieve steady-state conditions for
UDCA enrichment in the bile acid pool [21]. Therefore, it
might be logical to initiate UDCA prophylaxis earlier before
the transplant procedure.
In conclusion, the present results show that, in addition to
short-term beneﬁts, UDCA prophylaxis improves long-term
survival and reduces NRM without causing any adverse
effects.
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